SBC091-03

SBC091-03 is a small molecule therapeutic candidate being developed by SunRegen Healthcare for the treatment of optic atrophy. It is part of the company's SBC091 series, which focuses on neurodegenerative diseases of the retina and optic nerve. The drug's mechanism of action involves the modulation of the neuroglobin pathway and chaperone proteins, which are intended to provide neuroprotective, neurorescuing, and neurotrophic effects to retinal and optic nerve cells. The program specifically targets various forms of optic atrophy, including secondary optic atrophy and glaucoma-related optic atrophy. While SBC091-03 is associated with the company's lead compound SBC003, it is specifically designated for the optic atrophy program within their development pipeline.